SG10201804024VA - Formulations of azaindole compounds - Google Patents
Formulations of azaindole compoundsInfo
- Publication number
- SG10201804024VA SG10201804024VA SG10201804024VA SG10201804024VA SG10201804024VA SG 10201804024V A SG10201804024V A SG 10201804024VA SG 10201804024V A SG10201804024V A SG 10201804024VA SG 10201804024V A SG10201804024V A SG 10201804024VA SG 10201804024V A SG10201804024V A SG 10201804024VA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- pharmaceutical composition
- formulations
- hcl salt
- composition comprises
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 125000005334 azaindolyl group Chemical class N1N=C(C2=CC=CC=C12)* 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 6
- 150000003840 hydrochlorides Chemical class 0.000 abstract 3
- 239000000945 filler Substances 0.000 abstract 2
- 239000003002 pH adjusting agent Substances 0.000 abstract 2
- 241000712461 unidentified influenza virus Species 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
FORMULATIONS OF AZAINDOLE COMPOUNDS A pharmaceutical composition comprises: a) wt% to 9 5 wt% of a HCl salt of Compound (l) -xH2 0 by the weight of the pharmaceutical composition, wherein x is from 0 to 3; and b) 5 wt% to 9 5 wt% of a filler by the weight of the pharmaceutical composition. Another pharmaceutical composition comprises: a) 1 mg/ mL to 2 0 mg/ mL of Compound (1 ) in water; and b) 0 .0 1 M to0 .1 M of a pharmaceutically acceptable pH modifier. A method of preparing a pharmaceutical composition, comprising providing a mixture of Compound (1 ) that includes the HCl salt of Compound (l)-xH2 0 and the filler. Another method of preparing a pharmaceutical composition comprises mixing the HCl salt of Compound (l)' X3/ 4 0 and the pH modifier to form 1 mg/ mL to 2 0 mg/ mL of Compound (1 ) in water. Methods of reducing the amount of influenza viruses, inhibiting the replication of influenza viruses, andtreating influenza each independently employ such pharmaceutical compositions. No Suitable Figure
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361903840P | 2013-11-13 | 2013-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201804024VA true SG10201804024VA (en) | 2018-07-30 |
Family
ID=52001095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201804024VA SG10201804024VA (en) | 2013-11-13 | 2014-11-12 | Formulations of azaindole compounds |
Country Status (13)
Country | Link |
---|---|
US (3) | US20160250213A1 (en) |
EP (1) | EP3068434A1 (en) |
JP (2) | JP2016537347A (en) |
KR (1) | KR20160084465A (en) |
CN (1) | CN105848683A (en) |
AU (1) | AU2014348762A1 (en) |
CA (1) | CA2930105A1 (en) |
CL (1) | CL2016001111A1 (en) |
IL (2) | IL245587A0 (en) |
MX (1) | MX2016006197A (en) |
RU (1) | RU2685730C1 (en) |
SG (1) | SG10201804024VA (en) |
WO (1) | WO2015073491A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20156325B (en) | 2009-06-17 | 2015-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
UA118010C2 (en) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | INFLUENCES OF INFLUENZA VIRUS REPLICATION |
EP3421468B1 (en) | 2013-11-13 | 2020-11-04 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
RS59144B1 (en) | 2013-11-13 | 2019-09-30 | Vertex Pharma | Inhibitors of influenza viruses replication |
WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
AU2016368317B2 (en) | 2015-12-09 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
CN107759571B (en) | 2016-08-16 | 2021-03-02 | 广东东阳光药业有限公司 | Inhibitors of influenza virus replication and methods of use and uses thereof |
CN109641868B (en) | 2016-08-30 | 2021-12-03 | 广东东阳光药业有限公司 | Inhibitors of influenza virus replication and methods of use and uses thereof |
AU2017376541B2 (en) | 2016-12-15 | 2021-08-05 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
WO2018127096A1 (en) | 2017-01-05 | 2018-07-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
US10815232B2 (en) | 2017-01-24 | 2020-10-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereof |
WO2018157830A1 (en) | 2017-03-02 | 2018-09-07 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
EP3609502A1 (en) * | 2017-04-12 | 2020-02-19 | Vertex Pharmaceuticals Incorporated | Combination therapies for treating influenza virus infection |
WO2019043614A1 (en) * | 2017-08-31 | 2019-03-07 | Novartis Ag | Method for preparing granules |
US20210147413A1 (en) * | 2018-04-06 | 2021-05-20 | Janssen Pharmaceuticals, Inc. | Isothermal reactive crystallisation process for the preparation of a crystalline form of pimodivir hydrochloride hemihydrate |
WO2020058745A1 (en) * | 2018-09-18 | 2020-03-26 | Shionogi & Co., Ltd. | Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof |
BR112021009254A2 (en) * | 2018-11-13 | 2021-08-10 | Cocrystal Pharma, Inc. | formulations for influenza therapeutics |
KR20200106607A (en) * | 2019-03-05 | 2020-09-15 | 주식회사 코아팜바이오 | A pharmaceutical composition comprising oseltamivir |
US20200397784A1 (en) * | 2019-06-20 | 2020-12-24 | Janssen Pharmaceuticals, Inc. | Formulations of azaindole compounds |
CN112578034B (en) * | 2020-11-04 | 2022-02-11 | 广东众生睿创生物科技有限公司 | Quality control method of chiral amine micromolecules and salts thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681815A (en) * | 1993-06-28 | 1997-10-28 | Sophie Chen | Antiviral and antitumor agents |
ES2704482T3 (en) * | 2004-11-24 | 2019-03-18 | Meda Pharmaceuticals Inc | Compositions comprising azelastine and its methods of use |
US20120093738A1 (en) * | 2009-06-11 | 2012-04-19 | Rubicon Research Private Limited | Taste-masked oral formulations of influenza antivirals |
GEP20156325B (en) * | 2009-06-17 | 2015-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
-
2014
- 2014-11-12 MX MX2016006197A patent/MX2016006197A/en unknown
- 2014-11-12 KR KR1020167015721A patent/KR20160084465A/en not_active Application Discontinuation
- 2014-11-12 CA CA2930105A patent/CA2930105A1/en not_active Abandoned
- 2014-11-12 JP JP2016529960A patent/JP2016537347A/en active Pending
- 2014-11-12 EP EP14805749.0A patent/EP3068434A1/en not_active Withdrawn
- 2014-11-12 AU AU2014348762A patent/AU2014348762A1/en not_active Abandoned
- 2014-11-12 SG SG10201804024VA patent/SG10201804024VA/en unknown
- 2014-11-12 CN CN201480071163.7A patent/CN105848683A/en active Pending
- 2014-11-12 WO PCT/US2014/065144 patent/WO2015073491A1/en active Application Filing
- 2014-11-12 RU RU2016122609A patent/RU2685730C1/en active
-
2016
- 2016-05-10 IL IL245587A patent/IL245587A0/en unknown
- 2016-05-10 CL CL2016001111A patent/CL2016001111A1/en unknown
- 2016-05-10 US US15/150,497 patent/US20160250213A1/en not_active Abandoned
-
2018
- 2018-07-16 US US16/036,044 patent/US20180318301A1/en not_active Abandoned
-
2020
- 2020-09-30 US US17/038,749 patent/US20210008072A1/en not_active Abandoned
- 2020-10-21 IL IL278214A patent/IL278214A/en unknown
-
2021
- 2021-09-17 JP JP2021152005A patent/JP2021191796A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2016122609A (en) | 2017-12-18 |
US20180318301A1 (en) | 2018-11-08 |
IL245587A0 (en) | 2016-06-30 |
EP3068434A1 (en) | 2016-09-21 |
US20160250213A1 (en) | 2016-09-01 |
WO2015073491A1 (en) | 2015-05-21 |
RU2685730C1 (en) | 2019-04-23 |
CL2016001111A1 (en) | 2017-06-09 |
KR20160084465A (en) | 2016-07-13 |
AU2014348762A1 (en) | 2016-05-26 |
JP2021191796A (en) | 2021-12-16 |
CA2930105A1 (en) | 2015-05-21 |
JP2016537347A (en) | 2016-12-01 |
US20210008072A1 (en) | 2021-01-14 |
CN105848683A (en) | 2016-08-10 |
IL278214A (en) | 2020-11-30 |
MX2016006197A (en) | 2016-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201804024VA (en) | Formulations of azaindole compounds | |
PH12017500281A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
EA201590371A1 (en) | 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS | |
EA201291348A1 (en) | ACTIVATORS OF SOLUBLE GUANYLATZYCLASES | |
MX354102B (en) | Benzimidazole-proline derivatives. | |
BR112015023705A8 (en) | compounds, pharmaceutical compositions, uses of a compound, and method for synthesizing the compound of formula (ia) | |
MX2013001677A (en) | Stable formulations of linaclotide. | |
EA201690287A1 (en) | 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY | |
UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
BR112016010080A8 (en) | pyrazolopyrimidine compounds, pharmaceutical composition and their use | |
MX2013012289A (en) | Triazolopyridines. | |
CA2920410C (en) | Thienopiperidine derivative and use thereof | |
NZ714558A (en) | Formulation comprising a hypolipidemic agent | |
MX2016001422A (en) | Pharmaceutical compositions of fingolimod. | |
PH12015502632A1 (en) | Cxcr7 receptor modulators | |
HRP20191322T1 (en) | Antitumoral combination comprising cabazitaxel and cisplatin | |
EA201600394A1 (en) | TRICYCLIC COMPOUNDS OF PIPERIDINE | |
MX362858B (en) | Process for the preparation of pemetrexed and lysin salt thereof. | |
EA201490573A1 (en) | CONTAINING BENZOTHIAZOLONE | |
HRP20151340T1 (en) | Thieno[2, 3 -d]pyrimidine derivatives and their use to treat arrhythmia | |
EA201490363A1 (en) | NEW COMPOSITIONS BASED ON (TRIMETOXYPHENYLAMINO) Pyrimidinyls | |
MX362905B (en) | Combination treatment. | |
WO2014006635A3 (en) | Solid oral compositions of silodosin | |
HRP20231448T1 (en) | Use of delgocitinib for the treatment of chronic hand eczema | |
RS53612B1 (en) | Pharmaceutical solid compositions containing ibuprofen salts |